All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.
President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS
Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System
Baltimore, MD
All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.
President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS
Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System
Baltimore, MD
To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events.
Clinical Associate Professor and Vice Chair for Research
Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
University at Buffalo, Buffalo, NY
Nephrology
University of Alabama at Birmingham
Birmingham, AL
Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) program, Harvard Medical School
Physician, Renal Division
Brigham and Women’s Hospital/ Dana Farber Cancer Institute, Boston, MA